Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Ost

Showing results (151-160 of 334) with videos related to

Pageof 34
Sort By:
JAMA Oncology|November 25, 2020
Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysisEric J Lehrer, Raj Singh, Ming Wang, et al.
World Journal of Urology|May 13, 2018
Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancerAndrei Fodor, Andrea Lancia, Francesco Ceci, et al.
International Journal of Radiation Oncology, Biology, Physics|February 28, 2018
4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 TrialValérie Fonteyne, Camille Sarrazyn, Martijn Swimberghe, et al.
World Journal of Urology|April 4, 2018
Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urologyRoderick C N van den Bergh, Piet Ost, Christian Surcel, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 11, 2013
Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcomeValérie Fonteyne, Nicolaas Lumen, Piet Ost, et al.
Acta Oncologica (Stockholm, Sweden)|June 16, 2020
Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic reviewVerane Achard, Marta Bottero, Michel Rouzaud, et al.
Biomed Research International|February 20, 2015
Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcomeTom Claeys, Charles Van Praet, Nicolaas Lumen, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2011
High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapyPiet Ost, Cesare Cozzarini, Gert De Meerleer, et al.
Urologic Oncology|January 17, 2018
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trialSarah Buelens, Filip Poelaert, Bert Dhondt, et al.
The Lancet. Oncology|April 4, 2014
Radiotherapy for renal-cell carcinomaGert De Meerleer, Vincent Khoo, Bernard Escudier, et al.
Pageof 34

Showing results (151-160 of 334) with videos related to

Sort By:
Pageof 34
JAMA Oncology|November 25, 2020
Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysisEric J Lehrer, Raj Singh, Ming Wang, et al.
World Journal of Urology|May 13, 2018
Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancerAndrei Fodor, Andrea Lancia, Francesco Ceci, et al.
International Journal of Radiation Oncology, Biology, Physics|February 28, 2018
4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 TrialValérie Fonteyne, Camille Sarrazyn, Martijn Swimberghe, et al.
World Journal of Urology|April 4, 2018
Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urologyRoderick C N van den Bergh, Piet Ost, Christian Surcel, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 11, 2013
Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcomeValérie Fonteyne, Nicolaas Lumen, Piet Ost, et al.
Acta Oncologica (Stockholm, Sweden)|June 16, 2020
Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic reviewVerane Achard, Marta Bottero, Michel Rouzaud, et al.
Biomed Research International|February 20, 2015
Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcomeTom Claeys, Charles Van Praet, Nicolaas Lumen, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2011
High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapyPiet Ost, Cesare Cozzarini, Gert De Meerleer, et al.
Urologic Oncology|January 17, 2018
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trialSarah Buelens, Filip Poelaert, Bert Dhondt, et al.
The Lancet. Oncology|April 4, 2014
Radiotherapy for renal-cell carcinomaGert De Meerleer, Vincent Khoo, Bernard Escudier, et al.
Pageof 34